Stock Price, News, Quote and Profile of ICON PLC(NASDAQ:ICLR) stock

ICON PLC

NASDAQ:ICLR (12/27/2024, 8:00:02 PM)

After market: 212.29 0 (0%)

212.29

-1.53 (-0.72%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryLife Sciences Tools & Services

GICS SubIndustryLife Sciences Tools & Services

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%1.52%

Sales Q2Q%-1.22%

CRS12.53

6 Month-32.28%

Overview

Earnings (Last)10-23 2024-10-23/amc

Earnings (Next)02-19 2025-02-19/amc

Ins Owners0.65%

Inst Owners99.8%

Market Cap17.53B

Shares82.56M

PE15.13

Fwd PE13.91

Dividend YieldN/A

Analysts82.31

Short Float %1.62%

Short Ratio0.91

IPO05-15 1998-05-15

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Dublin, Dublin and currently employs 42,250 full-time employees. The firm is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. The company offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The firm's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. The company also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.